Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

By M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, C. Uprimny, P. Kovács, E. Guggenberg, R. Bale, I. Virgolini. 2007

972 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/5ec58ee08227159c64c2ef6c7d510640b394e8e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Thakker
2. N. Bax
3. N. Reed
4. J. Newell-Price
5. T. Meyer
6. J. Davar
7. A. Davies
8. J. Valle

Citations in the corpus

• Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) (2005, background): “There was an increase in the detection of unrecognised bone metastases, and additional sites of metastatic disease were identified.(90) However, CT is required to ensure detection of liver and lung metastases.”
• Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, unknown): “The sensitivity of CT to detect NETs is 61%–93% and the specificity is 71%–100% [12, 14, 15].”